Daiichi Pharmaceutical
Executive Summary
Files IND for DS-4152, an angiogenesis inhibitor for cancer that is an Arthrobacter soil bacteria derivative, Ft. Lee, New Jersey- based arm of the Japanese pharmaceutical company announces. Daiichi and the National Cancer Institute initiated a CRADA (Cooperative Research & Development Agreement) to study the compound for Kaposi's sarcoma. The IND proposes DS-4152 be studied in patients with solid tumors in San Antonio and separately in patients with Kaposi's at the University of Southern California. Daiichi is negotiating with NCI to begin a third study of additional dosing schedules of the compound, a sulfated polysaccharide.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth